Hemophagocytic Lymphohistiocytosis (HLH): A Survey Study on Pharmacists’ Practice Patterns and Perceptions

• ASH •
• 9 December, 2024 •
• •

Patients (pts) with Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI) Index-Confirmed Diagnosis of Malignancy-Associated HLH (mHLH) and Emapalumab Treatment

Naval Daver, Andrew Danquah, Didier Halimi, Jérôme Wojcik, Emmanuel Monnet

• ASH •
• 8 December, 2024 •
• •

Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab as a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study

Carl E. Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W. Leiding, Michael Marrone, Abiola Oladapo, Priti Pednekar, Kelly J. Walkovich, John Yee

• ACR •
• 14 November, 2024 •
• •

Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Uwe Ullman, Adnan Mahmood, Josefin Blomkvist, Brian D. Jamieson, Fabrizio De Benedetti

Available materials

• HS •
• 6 November, 2024 •
• •

Emapalumab in the Treatment of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (mHLH)

Naval Daver, Jérôme Wojcik, Didier Halimi, Emmanuel Monnet, Andrew Danquah

Available materials